X-linked Hypophosphatemia Disease Monitoring Program
← catalyst calendarNCT03651505 · readout ≤ 2,326 d
Sponsored by Ultragenyx Pharmaceutical Inc (industry) · RARE — their whole pipeline →. With Kyowa Kirin Co., Ltd..
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
782actual
Sites
38
Countries
Argentina, Brazil, Canada +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2018-07-16 | actual | When the study began enrolling |
| Primary completion | Dec 2032 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2032 | estimated | The whole study's end, after follow-up |
| First posted | 2018-08-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- X-linked Hypophosphatemia
- Hypophosphatemic Rickets
Intervention
- Other: No intervention
Primary outcomes
what the primary-completion date above is the date OFLong-Term Safety of Burosumab
measured 10 years
Long-Term Effectiveness of Burosumab
measured 10 years
Clinical Course of XLH Disease
measured 10 years
Publications
- PMID 40962182 — linked by the registry
- PMID 39151033 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · RARE's whole pipeline · Catalyst calendar · Every registered study · What changed